These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 23139320)

  • 21. [Method for the simultaneous detection of immunofluorescing antibodies to the causative agents of different hemorrhagic fevers].
    Lukashevich IS; van der Groen G
    Vopr Virusol; 1985; 30(5):624-6. PubMed ID: 3907144
    [No Abstract]   [Full Text] [Related]  

  • 22. [Indirect immunoenzyme method for the laboratory diagnosis of Lassa and Ebola hemorrhagic fevers].
    Ivanov AP; Tkachenko EA; van der Groen G; Butenko AM; Konstantinov OK
    Vopr Virusol; 1986; 31(2):186-90. PubMed ID: 3524001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hemorrhagic (Marburg, Ebola, Lassa, and Bolivian) fevers: epidemiology, clinical pictures, and treatment].
    Borisevich IV; Markin VA; Firsova IV; Evseev AA; Khamitov RA; Maksimov VA
    Vopr Virusol; 2006; 51(5):8-16. PubMed ID: 17087059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emergence of deadly viral haemorrhagic fever disease outbreaks in West Africa.
    Vega-Rodriguez W; Ly H
    Virulence; 2023 Dec; 14(1):2176980. PubMed ID: 36748841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ebola virus ecology: a continuing mystery.
    Feldmann H; Wahl-Jensen V; Jones SM; Ströher U
    Trends Microbiol; 2004 Oct; 12(10):433-7. PubMed ID: 15381189
    [No Abstract]   [Full Text] [Related]  

  • 26. Hiding the evidence: two strategies for innate immune evasion by hemorrhagic fever viruses.
    Hastie KM; Bale S; Kimberlin CR; Saphire EO
    Curr Opin Virol; 2012 Apr; 2(2):151-6. PubMed ID: 22482712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Research with the Marburg, Lassa and Ebola viruses].
    Pshenichnov VA; Makhlaĭ AA; Mikhaĭlov VV
    Vopr Virusol; 1993; 38(2):54-8. PubMed ID: 8059520
    [No Abstract]   [Full Text] [Related]  

  • 28. [Epidemiology of Viral Hemorrhagic Fever in Africa].
    Furuse Y
    Uirusu; 2021; 71(1):11-18. PubMed ID: 35526990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is the COVID-19 pandemic masking the deadlier Lassa fever epidemic in Nigeria?
    Reuben RC; Danladi MMA; Pennap GR
    J Clin Virol; 2020 Jul; 128():104434. PubMed ID: 32434707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lassa fever, Nigeria, 2003 and 2004.
    Omilabu SA; Badaru SO; Okokhere P; Asogun D; Drosten C; Emmerich P; Becker-Ziaja B; Schmitz H; Günther S
    Emerg Infect Dis; 2005 Oct; 11(10):1642-4. PubMed ID: 16355508
    [No Abstract]   [Full Text] [Related]  

  • 31. Research efforts to control highly pathogenic arenaviruses: a summary of the progress and gaps.
    Kerber R; Reindl S; Romanowski V; Gómez RM; Ogbaini-Emovon E; Günther S; ter Meulen J
    J Clin Virol; 2015 Mar; 64():120-7. PubMed ID: 25549822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. General introduction into the Ebola virus biology and disease.
    Zawilińska B; Kosz-Vnenchak M
    Folia Med Cracov; 2014; 54(3):57-65. PubMed ID: 25694096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preparation of polyvalent viral immunofluorescent intracellular antigens and use in human serosurveys.
    Johnson KM; Elliott LH; Heymann DL
    J Clin Microbiol; 1981 Nov; 14(5):527-9. PubMed ID: 7031084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New African hemorrhagic fevers].
    Pokrovskiĭ VV
    Ter Arkh; 1979; 51(11):119-23. PubMed ID: 392795
    [No Abstract]   [Full Text] [Related]  

  • 35. Marburg and Ebola virus infections in laboratory non-human primates: a literature review.
    Schou S; Hansen AK
    Comp Med; 2000 Apr; 50(2):108-23. PubMed ID: 10857001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs.
    Cashman KA; Wilkinson ER; Wollen SE; Shamblin JD; Zelko JM; Bearss JJ; Zeng X; Broderick KE; Schmaljohn CS
    Hum Vaccin Immunother; 2017 Dec; 13(12):3010-3019. PubMed ID: 29135337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outbreaks in a Rapidly Changing Central Africa - Lessons from Ebola.
    Munster VJ; Bausch DG; de Wit E; Fischer R; Kobinger G; Muñoz-Fontela C; Olson SH; Seifert SN; Sprecher A; Ntoumi F; Massaquoi M; Mombouli JV
    N Engl J Med; 2018 Sep; 379(13):1198-1201. PubMed ID: 30134126
    [No Abstract]   [Full Text] [Related]  

  • 38. Ebola virus: understanding the 2014 outbreak.
    Lorente JÁ; Blanch L; Esteban A
    Arch Bronconeumol; 2015 Feb; 51(2):59-60. PubMed ID: 25595937
    [No Abstract]   [Full Text] [Related]  

  • 39. The challenges of detecting and responding to a Lassa fever outbreak in an Ebola-affected setting.
    Hamblion EL; Raftery P; Wendland A; Dweh E; Williams GS; George RNC; Soro L; Katawera V; Clement P; Gasasira AN; Musa E; Nagbe TK
    Int J Infect Dis; 2018 Jan; 66():65-73. PubMed ID: 29138016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses.
    Mahanty S; Hutchinson K; Agarwal S; McRae M; Rollin PE; Pulendran B
    J Immunol; 2003 Mar; 170(6):2797-801. PubMed ID: 12626527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.